

Jeffrey L Lennox

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3384189/publications.pdf>

Version: 2024-02-01

87
papers

6,785
citations

76326

40
h-index

58581

82
g-index

87
all docs

87
docs citations

87
times ranked

6268
citing authors

#	ARTICLE	IF	CITATIONS
1	Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection. <i>New England Journal of Medicine</i> , 2008, 359, 339-354.	27.0	699
2	Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. <i>Lancet</i> , The, 2009, 374, 796-806.	13.7	621
3	Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2005, 40, 1559-1585.	5.8	545
4	Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection. <i>New England Journal of Medicine</i> , 2008, 359, 355-365.	27.0	498
5	Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2014, 59, e96-e138.	5.8	254
6	Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitorâ€“Sparing Antiretroviral Regimens for Treatment-Naïve Volunteers Infected With HIV-1. <i>Annals of Internal Medicine</i> , 2014, 161, 461.	3.9	225
7	Raltegravir Versus Efavirenz Regimens in Treatment-Naïve HIV-1â€“Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, 39-48.	2.1	211
8	A dangerous dilemma: management of infectious intracranial aneurysms complicating endocarditis. <i>Lancet Infectious Diseases</i> , The, 2006, 6, 742-748.	9.1	205
9	Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naïve HIV-1â€“Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, 77-85.	2.1	198
10	Longâ€“Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatmentâ€“Experienced Patients with Drugâ€“Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials. <i>Clinical Infectious Diseases</i> , 2010, 50, 605-612.	5.8	196
11	Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naïve Human Immunodeficiency Virus-1â€“Infected Patients: 156-Week Results From STARTMRK. <i>Clinical Infectious Diseases</i> , 2011, 53, 807-816.	5.8	149
12	HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. <i>Aids</i> , 2001, 15, 837-845.	2.2	144
13	Human Immunodeficiency Virus Type 1 Controllers but Not Noncontrollers Maintain CD4 T Cells Coexpressing Three Cytokines. <i>Journal of Virology</i> , 2007, 81, 12071-12076.	3.4	135
14	Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. <i>Vaccine</i> , 2001, 20, 545-553.	3.8	133
15	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2B6</i> and Efavirenzâ€“Containing Antiretroviral Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 726-733.	4.7	125
16	Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 587-596.	9.1	119
17	Ineffective Platelet Production in Thrombocytopenic Human Immunodeficiency Virusâ€“Infected Patients. <i>Blood</i> , 1998, 91, 3239-3246.	1.4	114
18	Impaired Hepatitis C Virus (HCV)-Specific Effector CD8 ⁺ T Cells Undergo Massive Apoptosis in the Peripheral Blood during Acute HCV Infection and in the Liver during the Chronic Phase of Infection. <i>Journal of Virology</i> , 2008, 82, 9808-9822.	3.4	93

#	ARTICLE	IF	CITATIONS
19	Dysregulated B Cell Expression of RANKL and OPG Correlates with Loss of Bone Mineral Density in HIV Infection. <i>PLoS Pathogens</i> , 2014, 10, e1004497.	4.7	93
20	Infrequent Diagnosis of Primary Human Immunodeficiency Virus Infection. <i>Archives of Internal Medicine</i> , 2003, 163, 2097.	3.8	88
21	Clinical Comparison of an Enhanced-Sensitivity Branched-DNA Assay and Reverse Transcription-PCR for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma. <i>Journal of Clinical Microbiology</i> , 1998, 36, 716-720.	3.9	88
22	A Randomized, Partially Blinded Phase 2 Trial of Antiretroviral Therapy, HIV-Specific Immunizations, and Interleukin-2 Cycles to Promote Efficient Control of Viral Replication (ACTG A5024). <i>Journal of Infectious Diseases</i> , 2006, 194, 1672-1676.	4.0	78
23	Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. <i>American Journal of Obstetrics and Gynecology</i> , 2001, 184, 279-285.	1.3	75
24	Correlation between Human Immunodeficiency Virus Type 1 RNA Levels in the Female Genital Tract and Immune Activation Associated with Ulceration of the Cervix. <i>Journal of Infectious Diseases</i> , 2000, 181, 1950-1956.	4.0	73
25	Disseminated <i>Mycobacterium avium</i> Complex Disease among Patients Infected with Human Immunodeficiency Virus, 1985-2000. <i>Clinical Infectious Diseases</i> , 2001, 33, 1938-1943.	5.8	71
26	Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257. <i>Clinical Infectious Diseases</i> , 2015, 60, 1842-1851.	5.8	67
27	HIV-1 RNA Rectal Shedding Is Reduced in Men With Low Plasma HIV-1 RNA Viral Loads and Is Not Enhanced by Sexually Transmitted Bacterial Infections of the Rectum. <i>Journal of Infectious Diseases</i> , 2011, 204, 761-767.	4.0	65
28	Metabolomics of Bronchoalveolar Lavage Differentiate Healthy HIV-1-Infected Subjects from Controls. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 579-585.	1.1	56
29	Prospective study of etiologic agents of community-acquired pneumonia in patients with HIV infection. <i>Aids</i> , 2002, 16, 85-95.	2.2	54
30	Tuberculosis Biomarker and Surrogate Endpoint Research Roadmap. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 972-979.	5.6	52
31	The Menstrual Cycle Does Not Affect Human Immunodeficiency Virus Type 1 Levels in Vaginal Secretions. <i>Journal of Infectious Diseases</i> , 2002, 185, 170-177.	4.0	50
32	Antiretroviral Therapy Initiated During Acute HIV Infection Fails to Prevent Persistent T-Cell Activation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 505-508.	2.1	49
33	Safety and Efficacy of Posaconazole in the Long-Term Treatment of Azole-Refractory Oropharyngeal and Esophageal Candidiasis in Patients with HIV Infection. <i>HIV Clinical Trials</i> , 2007, 8, 86-97.	2.0	47
34	Detection of latent tuberculosis among HIV-infected patients after initiation of highly active antiretroviral therapy. <i>Aids</i> , 2003, 17, 1102-1104.	2.2	47
35	A Switch in Therapy to a Reverse Transcriptase Inhibitor Sparing Combination of Lopinavir/Ritonavir and Raltegravir in Virologically Suppressed HIV-Infected Patients: A Pilot Randomized Trial to Assess Efficacy and Safety Profile: The KITE Study. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1196-1206.	1.1	46
36	A Study of Discontinuing Maintenance Therapy in Human Immunodeficiency Virus-Infected Subjects with Disseminated <i>Mycobacterium avium</i> Complex: AIDS Clinical Trial Group 393 Study Team. <i>Journal of Infectious Diseases</i> , 2003, 187, 1046-1052.	4.0	44

#	ARTICLE	IF	CITATIONS
37	Specificity of the Antibody Response to the Pneumococcal Polysaccharide and Conjugate Vaccines in Human Immunodeficiency Virus-Infected Adults. <i>Vaccine Journal</i> , 2004, 11, 137-141.	2.6	43
38	Bilirubin Is Inversely Associated With Cardiovascular Disease Among HIV-Positive and HIV-Negative Individuals in VACS (Veterans Aging Cohort Study). <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	43
39	Atovaquone is effective treatment for the symptoms of gastrointestinal microsporidiosis in HIV-1-infected patients. <i>Aids</i> , 1996, 10, 619-624.	2.2	42
40	A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naïve HIV-infected Patients: A Phase IIb Trial. <i>Clinical Infectious Diseases</i> , 2016, 63, 663-671.	5.8	42
41	Outcomes for critically ill patients with HIV and severe sepsis in the era of highly active antiretroviral therapy. <i>Journal of Critical Care</i> , 2012, 27, 51-57.	2.2	41
42	Patterns of Antibody Recognition of Selected Conserved Amino Acid Sequences from the HIV Envelope in Sera from Different Stages of HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 1989, 5, 33-39.	1.1	39
43	Predictors of Success with Highly Active Antiretroviral Therapy in an Antiretroviral-Naïve Urban Population. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 133-138.	1.1	37
44	Increased Survival of Persons with Tuberculosis and Human Immunodeficiency Virus Infection, 1991-2000. <i>Clinical Infectious Diseases</i> , 2002, 34, 1002-1007.	5.8	34
45	Liver Enzymes Elevation and Immune Reconstitution Among Treatment-Naïve HIV-Infected Patients Instituting Antiretroviral Therapy. <i>American Journal of the Medical Sciences</i> , 2007, 334, 334-341.	1.1	33
46	Imported Malaria at an Inner-City Hospital in the United States. <i>American Journal of the Medical Sciences</i> , 2005, 329, 6-12.	1.1	32
47	High Prevalence of Persistent Parasitic Infections in Foreign-Born, HIV-Infected Persons in the United States. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1034.	3.0	32
48	Risk of <i>Cryptosporidium parvum</i> Transmission between Hospital Roommates. <i>Clinical Infectious Diseases</i> , 2000, 31, 947-950.	5.8	31
49	Diversity, Divergence, and Evolution of Cell-Free Human Immunodeficiency Virus Type 1 in Vaginal Secretions and Blood of Chronically Infected Women: Associations with Immune Status. <i>Journal of Virology</i> , 2005, 79, 9799-9809.	3.4	31
50	Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1-Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK. <i>HIV Clinical Trials</i> , 2012, 13, 228-232.	2.0	30
51	Outcomes by Sex Following Treatment Initiation With Atazanavir Plus Ritonavir or Efavirenz With Abacavir/Lamivudine or Tenofovir/Emtricitabine. <i>Clinical Infectious Diseases</i> , 2014, 58, 555-563.	5.8	30
52	Oral sampling and human papillomavirus genotyping in HIV-infected patients. <i>Journal of Oral Pathology and Medicine</i> , 2012, 41, 288-291.	2.7	29
53	Anti-Retroviral Therapy Is Associated with Decreased Alveolar Glutathione Levels Even in Healthy HIV-Infected Individuals. <i>PLoS ONE</i> , 2014, 9, e88630.	2.5	27
54	Immune Activation Mediated Change in Alpha-1-Acid Glycoprotein: Impact on Total and Free Lopinavir Plasma Exposure. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1539-1548.	2.0	26

#	ARTICLE	IF	CITATIONS
55	T-cell receptor activator of nuclear factor- κ B ligand/osteoprotegerin imbalance is associated with HIV-induced bone loss in patients with higher CD4+ T-cell counts. <i>Aids</i> , 2018, 32, 885-894.	2.2	24
56	Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals. <i>Journal of NeuroVirology</i> , 2017, 23, 106-112.	2.1	22
57	Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts \geq 200 Cells/mL Virologically Suppressed on Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2018, 67, 1712-1719.	5.8	22
58	Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large Human Immunodeficiency Virus Treatment-naive Clinical Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 1044-1047.	5.8	22
59	Identification of rare HIV-1-infected patients with extreme CD4+ T cell decline despite ART-mediated viral suppression. <i>JCI Insight</i> , 2019, 4, .	5.0	21
60	Macrolide-Resistant Pneumococcal Endocarditis and Epidural Abscess that Develop during Erythromycin Therapy. <i>Clinical Infectious Diseases</i> , 2003, 36, e19-e25.	5.8	20
61	Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1063-1071.	2.0	19
62	Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv085.	0.9	19
63	Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infection. <i>Aids</i> , 2003, 17, 2025-2033.	2.2	17
64	Lopinavir/Ritonavir Pharmacokinetic Profile: Impact of Sex and Other Covariates Following a Change From Twice-Daily to Once-Daily Therapy. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 970-977.	2.0	17
65	Viral load response to a pneumococcal conjugate vaccine, polysaccharide vaccine or placebo among HIV-infected patients. <i>Aids</i> , 2002, 16, 1421-1423.	2.2	15
66	Integrated Population Pharmacokinetic/Viral Dynamic Modelling of Lopinavir/Ritonavir in HIV-1 Treatment-Naïve Patients. <i>Clinical Pharmacokinetics</i> , 2014, 53, 361-371.	3.5	13
67	Detection of Infectious Human Immunodeficiency Virus Type 1 in Female Genital Secretions by a Short-Term Culture Method. <i>Journal of Clinical Microbiology</i> , 2003, 41, 4081-4088.	3.9	12
68	Pandemic Influenza: Implications for Programs Controlling for HIV Infection, Tuberculosis, and Chronic Viral Hepatitis. <i>American Journal of Public Health</i> , 2009, 99, S333-S339.	2.7	12
69	The use of HIV-1 integrase inhibitors in antiretroviral naive patients. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 409-414.	3.8	12
70	Antiretroviral Therapy-Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial. <i>Clinical Infectious Diseases</i> , 2020, 71, 1655-1663.	5.8	12
71	Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults. <i>PLoS Genetics</i> , 2021, 17, e1009464.	3.5	11
72	Executive Summary: Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2014, 59, 1203-1207.	5.8	10

#	ARTICLE	IF	CITATIONS
73	Lack of effect of compartmentalized drug resistance mutations on HIV-1 pol divergence in antiretroviral-experienced women. <i>Aids</i> , 2010, 24, 1361-1366.	2.2	9
74	Preliminary study of a novel cognitive assessment device for the evaluation of HIV-associated neurocognitive impairment. <i>Journal of NeuroVirology</i> , 2016, 22, 816-822.	2.1	8
75	Culturally-adapted and audio-technology assisted HIV/AIDS awareness and education program in rural Nigeria: a cohort study. <i>BMC International Health and Human Rights</i> , 2010, 10, 2.	2.5	6
76	Female Genital Tract Shedding of CXCR4-Tropic HIV Type 1 Is Associated with a Majority Population of CXCR4-Tropic HIV Type 1 in Blood and Declining CD4+Cell Counts. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1524-1532.	1.1	5
77	HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. <i>AIDS and Behavior</i> , 2016, 20, 2983-2995.	2.7	5
78	Distinct cellular immune properties in cerebrospinal fluid are associated with cognition in HIV-infected individuals initiating antiretroviral therapy. <i>Journal of Neuroimmunology</i> , 2020, 344, 577246.	2.3	5
79	HIV Antibody Screening in a General Hospital Population. <i>JAMA - Journal of the American Medical Association</i> , 1987, 257, 2914.	7.4	4
80	Antiretroviral therapy: When to start and which drugs to use. <i>Current Infectious Disease Reports</i> , 2008, 10, 332-339.	3.0	4
81	Global HIV/AIDS Medicine. <i>Emerging Infectious Diseases</i> , 2008, 14, 1006b-1007.	4.3	4
82	Pharmacokinetics of an Indinavir-Ritonavir-Fosamprenavir Regimen in Patients with Human Immunodeficiency Virus. <i>Pharmacotherapy</i> , 2008, 28, 74-81.	2.6	3
83	Methylprednisolone for Coronavirus Disease 2019 (COVID-19): Was Benjamin Rush Prescient?. <i>Clinical Infectious Diseases</i> , 2021, 72, e382-e383.	5.8	2
84	Abacavir/lamivudine fixed dose combination in the treatment of patients with HIV infection. <i>HIV Therapy</i> , 2009, 3, 19-29.	0.6	1
85	Medical care of the HIV-infected surgical patient. , 0, , 307-316.		0
86	Outcomes For ICU Patients With HIV And Severe Sepsis In The HAART Era. , 2010, , .		0
87	HIV infection. , 0, , 282-291.		0